Edesa Biotech (EDSA) Total Liabilities (2013 - 2026)
Edesa Biotech (EDSA) posted Total Liabilities of $14.7 million for Q4 2025, up 8.72% sequentially from $13.5 million in Q3 2025, and up 253.26% YoY from $4.2 million in Q4 2024.
Edesa Biotech (EDSA) Total Liabilities (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Total Liabilities for 13 years, with the latest figure at $14.7 million in Q4 2025.
- Quarterly Total Liabilities rose 253.26% year-over-year to $14.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.7 million (up 253.26% YoY) and the FY2025 annual result came in at $13.5 million, up 638.23% from the prior year.
- Total Liabilities advanced to $14.7 million in Q4 2025 per EDSA's latest filing, from $13.5 million in the prior quarter.
- Over five years, Total Liabilities peaked at $16.5 million in Q1 2025 and troughed at $1.1 million in Q2 2021.
- A 5-year average of $4.9 million and a median of $2.2 million in 2022 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities plunged 72.49% in 2023, then surged 665.06% in 2025.
- Over 5 years, Total Liabilities stood at $1.8 million in 2021, then declined by 21.89% to $1.4 million in 2022, then surged by 41.79% to $2.0 million in 2023, then surged by 109.58% to $4.2 million in 2024, then surged by 253.26% to $14.7 million in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $14.7 million, $13.5 million, and $14.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 10.03 Bn |
| 10 | Edesa Biotech | 41.43 Mn | 41.43 Mn | - | 12.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.72 Mn |
| Dec 31, 2025 | 14.71 Mn |
| Sep 30, 2025 | 13.53 Mn |
| Jun 30, 2025 | 14.80 Mn |
| Mar 31, 2025 | 16.45 Mn |
| Dec 31, 2024 | 4.16 Mn |
| Sep 30, 2024 | 1.83 Mn |
| Jun 30, 2024 | 2.36 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Dec 31, 2023 | 1.99 Mn |
| Sep 30, 2023 | 1.84 Mn |
| Jun 30, 2023 | 1.57 Mn |
| Mar 31, 2023 | 1.67 Mn |
| Dec 31, 2022 | 1.40 Mn |
| Sep 30, 2022 | 2.18 Mn |
| Jun 30, 2022 | 5.70 Mn |
| Mar 31, 2022 | 3.38 Mn |
| Dec 31, 2021 | 1.79 Mn |
| Sep 30, 2021 | 1.53 Mn |
| Jun 30, 2021 | 1.07 Mn |